Investor Alert

press release

Sept. 7, 2021, 8:01 a.m. EDT

BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021

NEW YORK, Sep 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. ("BeyondSpring") /zigman2/quotes/204570570/composite BYSI +2.24% , a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the second quarter ended June 30, 2021 and provide an update on recent corporate events on Friday, September 10, 2021 at 8:00 AM Eastern Time. Details for the conference call are below:

Friday, September 10 @ 8:00 AM Eastern Time
Domestic: 877-451-6152
International: 201-389-0879
Conference ID: 13722968
Webcast: http://public.viavid.com/index.php?id=146495

An archived replay of the webcast will be available for 90 days on BeyondSpring's website at www.beyondspringpharma.com under "Events & Presentations" in the Investors section.

About BeyondSpring
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring's first-in-class lead asset plinabulin, is being developed as a "pipeline in a drug" in various cancer indications as direct anti-cancer agent and to prevent chemotherapy induced neutropenia (CIN). Plinabulin and G-CSF combination has filed for approval and has received Priority Review and breakthrough designation in the U.S. and China for the prevention of CIN with a PDUFA date of November 30, 2021 in the U.S. In DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2 [nd] /3 [rd] line NSCLC (EGFR wild type). Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1 / PD-L1 antibodies in seven different cancers. In addition to plinabulin, BeyondSpring's extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577

Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

US : U.S.: Nasdaq
$ 4.11
+0.09 +2.24%
Volume: 5.12M
Dec. 6, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$157.24 million
Rev. per Employee

Partner Center

Link to MarketWatch's Slice.